{"id":"iv-acetaminophen-treatment-a","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Infusion site pain"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1647","moleculeType":"Small molecule","molecularWeight":"327.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acetaminophen works primarily through inhibition of cyclooxygenase (COX) enzymes in the brain and spinal cord, reducing prostaglandin production and thereby lowering pain perception and body temperature set point. The intravenous formulation provides rapid systemic delivery for faster onset of analgesia and antipyresis compared to oral routes. It does not have significant peripheral anti-inflammatory activity like NSAIDs.","oneSentence":"Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:26.613Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Management of mild to moderate pain"},{"name":"Reduction of fever"},{"name":"Management of moderate pain with opioids"}]},"trialDetails":[{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT06009926","phase":"PHASE2","title":"Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-04","conditions":"Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Occupational Malignant Neoplasm","enrollment":72},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":900},{"nctId":"NCT06170788","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":614},{"nctId":"NCT07423650","phase":"PHASE4","title":"Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy","status":"RECRUITING","sponsor":"Iuliu Hatieganu University of Medicine and Pharmacy","startDate":"2026-03","conditions":"Pancreatoduodenectomy, Pain Management, Opioid Analgesia","enrollment":93},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT06393374","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-24","conditions":"Triple-Negative Breast Cancer","enrollment":1530},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT05319730","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":230},{"nctId":"NCT07486089","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)","enrollment":60},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT03258593","phase":"PHASE1","title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-07","conditions":"Urinary Bladder Neoplasms","enrollment":15},{"nctId":"NCT06445972","phase":"PHASE1, PHASE2","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-07","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":210},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT06043323","phase":"PHASE2","title":"A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-08","conditions":"Follicular Lymphoma","enrollment":20},{"nctId":"NCT06780111","phase":"PHASE1, PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":298},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT06201676","phase":"PHASE4","title":"Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-02-28","conditions":"Orthopaedic Trauma, Chronic Opioid Use","enrollment":458},{"nctId":"NCT06356571","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-17","conditions":"Plasma Cell Myeloma Refractory","enrollment":64},{"nctId":"NCT06994442","phase":"PHASE3","title":"Optimizing Pain Treatment in Children On Mechanical Ventilation","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-12-29","conditions":"Mechanical Ventilation, Pediatric Acute Respiratory Failure, Analgesics, Opioid","enrollment":644},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT07419295","phase":"PHASE3","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-17","conditions":"Bladder Cancer","enrollment":590},{"nctId":"NCT06074588","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-12","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":556},{"nctId":"NCT07397117","phase":"NA","title":"Comparing Ultrasound-Guided Transgluteal Nerve Block to Standard Care","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-02-01","conditions":"Sciatica Acute","enrollment":100},{"nctId":"NCT04221477","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Lupus Nephritis","enrollment":271},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":"Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":13},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT06309693","phase":"NA","title":"Postoperative Pain Management Following Robotic Assisted Sacrocolpopexy","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2025-01-22","conditions":"Pelvic Organ Prolapse, Post Operative Pain","enrollment":70},{"nctId":"NCT06132958","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Endometrial Cancer","enrollment":710},{"nctId":"NCT05211336","phase":"PHASE1","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-04-19","conditions":"Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS","enrollment":14},{"nctId":"NCT04629248","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Primary Membranous Nephropathy","enrollment":142},{"nctId":"NCT06460961","phase":"PHASE1","title":"A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-14","conditions":"Neoplasm Metastasis","enrollment":168},{"nctId":"NCT03978767","phase":"PHASE2","title":"Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-06-10","conditions":"Preeclampsia Severe, Preeclampsia Postpartum","enrollment":287},{"nctId":"NCT05704049","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":118},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":"Plasma Cell Myeloma","enrollment":337},{"nctId":"NCT05065554","phase":"PHASE2","title":"ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shayna Sarosiek, MD","startDate":"2021-11-16","conditions":"IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral","enrollment":12},{"nctId":"NCT05340582","phase":"PHASE2","title":"Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants","status":"RECRUITING","sponsor":"Mount Sinai Hospital, Canada","startDate":"2022-12-12","conditions":"Patent Ductus Arteriosus After Premature Birth","enrollment":310},{"nctId":"NCT05035407","phase":"PHASE1","title":"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-08","conditions":"Kita-kyushu Lung Cancer Antigen 1, Human","enrollment":36},{"nctId":"NCT03368664","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-10-24","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT04702256","phase":"PHASE3","title":"Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-09","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus (SLE)","enrollment":196},{"nctId":"NCT05405166","phase":"PHASE3","title":"SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-23","conditions":"Plasma Cell Myeloma Recurrent","enrollment":531},{"nctId":"NCT04668833","phase":"PHASE2","title":"ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-09-29","conditions":"Solid Tumor Malignancies","enrollment":26},{"nctId":"NCT06019728","phase":"PHASE4","title":"A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-11-10","conditions":"Fabry's Disease","enrollment":8},{"nctId":"NCT06955741","phase":"PHASE1","title":"A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-05-05","conditions":"Healthy Volunteer","enrollment":46},{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT03493945","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-01","conditions":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm","enrollment":59},{"nctId":"NCT03032601","phase":"NA","title":"Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis","status":"ENROLLING_BY_INVITATION","sponsor":"Thomas Jefferson University","startDate":"2017-01-05","conditions":"Multiple Sclerosis","enrollment":55},{"nctId":"NCT04294459","phase":"PHASE1, PHASE2","title":"Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-06-18","conditions":"Immune System Disorder","enrollment":23},{"nctId":"NCT05842044","phase":"PHASE2","title":"NSAID Use After Robotic Partial Nephrectomy","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-09-15","conditions":"Kidney Cancer, Renal Cancer, Renal Neoplasm","enrollment":110},{"nctId":"NCT05231460","phase":"PHASE4","title":"Pain Management Study","status":"ENROLLING_BY_INVITATION","sponsor":"University of Arizona","startDate":"2022-02-18","conditions":"Pain, Postoperative","enrollment":244},{"nctId":"NCT05779930","phase":"EARLY_PHASE1","title":"Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL","status":"NOT_YET_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2025-10","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory","enrollment":12},{"nctId":"NCT07109284","phase":"PHASE2","title":"SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2025-09","conditions":"ER+HER2- Breast Cancer","enrollment":55},{"nctId":"NCT06935331","phase":"PHASE4","title":"Prospective Opioid-Free AIS Fusion","status":"NOT_YET_RECRUITING","sponsor":"OrthoCarolina Research Institute, Inc.","startDate":"2025-08-15","conditions":"Adolescent Idiopathic Scoliosis (AIS)","enrollment":58},{"nctId":"NCT03805932","phase":"PHASE1","title":"Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-03","conditions":"Hairy Cell Leukemia","enrollment":18},{"nctId":"NCT03456817","phase":"PHASE2","title":"HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2020-07-01","conditions":"Graft-versus-host-disease, Relapse","enrollment":68},{"nctId":"NCT06950840","phase":"PHASE4","title":"Antipyretic Treatment for Intrapartum Fever: Dipyrone vs Acetaminophen (RCT)","status":"NOT_YET_RECRUITING","sponsor":"Wolfson Medical Center","startDate":"2025-08-01","conditions":"Intrapartum Fever, Chorioamnionitis","enrollment":140},{"nctId":"NCT07037888","phase":"PHASE4","title":"Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy: A Prospective Double-Blinded Randomized Controlled Trial","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2023-12-13","conditions":"Femoracetabular Impingement, Hip Arthroscopy","enrollment":100},{"nctId":"NCT04165096","phase":"PHASE2","title":"KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-01-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":128},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT01059786","phase":"PHASE2","title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-01","conditions":"Hairy Cell Leukemia","enrollment":69},{"nctId":"NCT07017452","phase":"PHASE3","title":"Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia","status":"NOT_YET_RECRUITING","sponsor":"University of Manitoba","startDate":"2025-08","conditions":"Benign Prostate Hypertrophy(BPH)","enrollment":48},{"nctId":"NCT06479122","phase":"PHASE4","title":"Efficacy of Acetaminophen Alone Versus Combination of Acetaminophen/Ibuprofen After Cesarean Section","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-10-09","conditions":"Cesarean Section, Postoperative Pain","enrollment":84},{"nctId":"NCT03554473","phase":"PHASE1, PHASE2","title":"M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-11","conditions":"Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer","enrollment":37},{"nctId":"NCT04765449","phase":"PHASE1","title":"Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2021-09-15","conditions":"Covid19","enrollment":30},{"nctId":"NCT03020875","phase":"PHASE4","title":"IV vs Oral Acetaminophen in Spine Fusion Perioperative Care","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital for Special Surgery, New York","startDate":"2017-01","conditions":"Multimodal Analgesic Approach","enrollment":166},{"nctId":"NCT02651324","phase":"PHASE4","title":"Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis","status":"COMPLETED","sponsor":"Albany Medical College","startDate":"2013-05","conditions":"Idiopathic Scoliosis, Post-operative Pain","enrollment":50},{"nctId":"NCT05974501","phase":"PHASE4","title":"Pre vs Post Block in Total Knee Arthroplasty (TKA)","status":"COMPLETED","sponsor":"University of Miami","startDate":"2023-09-29","conditions":"Knee Osteoarthritis, Arthroplasty Complications, Postoperative Pain","enrollment":84},{"nctId":"NCT04599634","phase":"PHASE1","title":"Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-16","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma","enrollment":11},{"nctId":"NCT03987022","phase":"PHASE4","title":"ICE-T Pain Regimen for Total Laparoscopic Hysterectomy","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2019-08-01","conditions":"Opioid Substitution Treatment","enrollment":66},{"nctId":"NCT06603051","phase":"NA","title":"The Effect of Pre-Operative Cryoneurolysis on Post-Operative Narcotic Consumption in Patients Undergoing Autograft ACL Reconstruction","status":"RECRUITING","sponsor":"Virtua Health, Inc.","startDate":"2024-08-28","conditions":"ACL Repair","enrollment":20},{"nctId":"NCT04148495","phase":"PHASE4","title":"Intravenous Acetaminophen and Morphine Versus Intravenous Morphine Alone for Acute Pain in the Emergency Department","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2019-12-03","conditions":"Pain Management","enrollment":415},{"nctId":"NCT06557330","phase":"PHASE2","title":"MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2025-06","conditions":"Lymphoma, Indolent Non-hodgkin Lymphoma","enrollment":24},{"nctId":"NCT03711734","phase":"NA","title":"Acupuncture ACL (Anterior Cruciate Ligament)","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2018-11-01","conditions":"ACL, ACL Injury, Anterior Cruciate Ligament Injury","enrollment":40},{"nctId":"NCT03836014","phase":"PHASE3","title":"Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-07-25","conditions":"Multiple Myeloma in Relapse","enrollment":436},{"nctId":"NCT06721819","phase":"PHASE3","title":"The SCOPE Trial: Sleep, Cognition, and Pain Bundle Vs. ERAS-cardiac for Postoperative Delirium","status":"NOT_YET_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2025-02-01","conditions":"Delirium, Postoperative, Delirium in Old Age","enrollment":406},{"nctId":"NCT03472872","phase":"PHASE4","title":"A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache","status":"WITHDRAWN","sponsor":"Corewell Health South","startDate":"2017-09-05","conditions":"Headache","enrollment":""},{"nctId":"NCT04176419","phase":"PHASE3","title":"Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2020-01-17","conditions":"Postoperative Pain Control, Opioid Consumption","enrollment":30},{"nctId":"NCT06656299","phase":"NA","title":"EOIB for Laparoscopic Cholecystectomy","status":"RECRUITING","sponsor":"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","startDate":"2024-10-30","conditions":"Cholecystitis, Cholecystitis, Acute, Cholecystitis, Chronic","enrollment":60},{"nctId":"NCT05158270","phase":"NA","title":"Erector Spinae Plane Block Versus Subcostal Anterior Quadratus Lumborum Block in Laparoscopic Cholecystectomy","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2021-11-15","conditions":"Laparoscopic Cholecystectomy, Quadratus Lumborum Block, Erector Spinae Plane Block","enrollment":81},{"nctId":"NCT03467750","phase":"PHASE4","title":"Effect of Ketorolac on Post Adenotonsillectomy Pain","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-07-19","conditions":"Obstructive Sleep Apnea","enrollment":63},{"nctId":"NCT05338099","phase":"PHASE1","title":"Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)","status":"COMPLETED","sponsor":"ENCell","startDate":"2022-01-18","conditions":"Duchenne Muscular Dystrophy","enrollment":7},{"nctId":"NCT04123717","phase":"EARLY_PHASE1","title":"Pilot Study Comparison Of Intravenous Ibuprofen And Intravenous Paracetamol In Management Of Pediatric Fever","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2019-10-11","conditions":"Fever","enrollment":147},{"nctId":"NCT05574504","phase":"PHASE2","title":"Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy","status":"WITHDRAWN","sponsor":"AdventHealth","startDate":"2023-05-08","conditions":"Metastatic Cancer, Urothelial Carcinoma","enrollment":""},{"nctId":"NCT04811209","phase":"","title":"MCID and PASS for Acute Pain and Quality of Recovery After Orthopedic Surgery","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-06-21","conditions":"Pain Management","enrollment":300},{"nctId":"NCT06036979","phase":"NA","title":"Preoperative Erector Spinae Plane Block Versus Paravertebral Plane Block in Decreasing Post Mastectomy Pain Syndrome","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute, Egypt","startDate":"2024-07-01","conditions":"Chronic Postoperative Pain","enrollment":51},{"nctId":"NCT04347720","phase":"","title":"Canadian National PDA Treatment Study","status":"COMPLETED","sponsor":"IWK Health Centre","startDate":"2020-01-01","conditions":"Patent Ductus Arteriosus, Extreme Prematurity","enrollment":1663},{"nctId":"NCT01209455","phase":"NA","title":"Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2011-01-03","conditions":"Poisoning","enrollment":24},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT04580121","phase":"PHASE1","title":"A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-11-04","conditions":"Acute Myeloid Leukemia","enrollment":59},{"nctId":"NCT02933255","phase":"PHASE1, PHASE2","title":"PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-18","conditions":"Prostate Cancer","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["OFIRMEV"],"phase":"marketed","status":"active","brandName":"IV Acetaminophen (Treatment A)","genericName":"IV Acetaminophen (Treatment A)","companyName":"Mallinckrodt","companyId":"mallinckrodt","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever. Used for Management of mild to moderate pain, Reduction of fever, Management of moderate pain with opioids.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}